SCHEMBL2078377

SCHEMBL2078377

CC(C)(C)OC(=O)N1CCC(c2ccccc2N)C1

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 2/20 0.50
HPGDS O60760 2/20 0.49
PDE4B Q07343 1/20 0.48
USP30 Q70CQ3 4/20 0.47
NAMPT P43490 1/20 0.47
KDM4E B2RXH2 2/20 0.46
MAPT P10636 1/20 0.46
THRB P10828 1/20 0.46
JAK2 O60674 1/20 0.46
JAK1 P23458 1/20 0.46
PKM P14618 1/20 0.46
EGFR P00533 1/20 0.45
SRC P12931 1/20 0.45
ALOX5AP P20292 1/20 0.44
FEN1 P39748 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL73493 0.92 GPR119 (0.55) GPR119HPGDSNAMPTKDM4EMAPT
SCHEMBL30534946 0.92 GPR119 (0.55) GPR119HPGDSNAMPTKDM4EMAPT
SCHEMBL3436375 0.87 HSD11B1 (0.54) GPR119HPGDSPDE4BUSP30NAMPT
SCHEMBL14861450 0.85 PARP1 (0.49) GPR119HPGDSPDE4BUSP30NAMPT
SCHEMBL22619177 0.85 PDE4B (0.45) GPR119HPGDSPDE4BUSP30NAMPT
SCHEMBL21352382 0.85 GPR119 (0.50) GPR119HPGDSPDE4BUSP30NAMPT
SCHEMBL28334298 0.85 GPR119 (0.50) GPR119HPGDSPDE4BUSP30NAMPT
SCHEMBL25044033 0.84 MEN1 (0.59) GPR119HPGDSPDE4B
SCHEMBL4939245 0.84 GPR119 (0.52) GPR119HPGDSPDE4BUSP30NAMPT
SCHEMBL19400865 0.83 USP30 (0.53) GPR119HPGDSUSP30JAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163746-B2 Azolecarboxamide derivative ASTELLAS PHARMA INC. (JP) 2012-04-24 US disclosed
US-8163746-B2 Azolecarboxamide derivative ASTELLAS PHARMA INC. (JP) 2012-04-24 US disclosed
US-8163746-B2 Azolecarboxamide derivative ASTELLAS PHARMA INC. (JP) 2012-04-24 US disclosed
US-20090286766-A1 AZOLECARBOXAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-11-19 US disclosed
US-20090286766-A1 AZOLECARBOXAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-11-19 US disclosed
US-20090286766-A1 AZOLECARBOXAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-11-19 US disclosed
EP-2009005-A1 AZOLECARBOXAMIDE DERIVATIVE Astellas Pharma Inc. (JP) 2008-12-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286766-A1 AZOLECARBOXAMIDE DERIVATIVE GPR17, NTRK1, TRPV1 GPR119 77/4885HPGDS 2971/4885PDE4B 567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.